COMMUNITY INVESTMENT IN THE PHARMACEUTICAL INDUSTRY
According to our latest Corporate Giving by the FTSE 100 research, pharmaceutical companies have consistently been the most generous sector in terms of giving. They have donated over £6.7 billion to charitable causes over the last seven years, the equivalent of 7.5% of pre-tax profit over the same period. Although part of this figure will include a financial value assigned to product donations that healthcare companies are uniquely placed to provide, as a benchmark this is still extremely high, with average levels across the FTSE 100 at just 2.4%.
From intrinsic 'Shared Value' recognition, to regulatory scrutiny and reputation management, there are a number of drivers behind this level of giving. What is consistent is a near uniform approach to transparency and disclosure evidenced through initiatives such as the EFPIA’s Disclosure Code. We've also seen this first hand through our FTSE 100 research - Healthcare was one of only five industries where all companies provided data on charitable donations.
At CAF we partner with leading pharmaceutical companies such as AstraZeneca, GSK and ViiV Healthcare to support them with these global philanthropic programmes. As an international organisation, we are able to navigate complex legal, political, fiscal and operational issues, enabling our clients to make de-risked, international donations at scale whilst also ensuring UK tax efficiency. Our programmes are designed to enable our clients to maximise their focus on growing their impact whilst ensuring a robust, transparent approach to distributing charitable funds.
We also offer leading strategic advisory services, enabling our clients to develop and express their social purpose, translating their ambitions into innovative, high impact programmes and facilitating a structured approach to impact reporting, programme learning and innovation.